Tranexamic acid is not one of Korea's nine
It is easy to assume the ingredient printed largest on the front panel is the one holding up the whitening claim. Korean rules are not built that way. Korea notifies nine whitening actives and tranexamic acid is not among them. Japan approved the same molecule as a whitening active in 2002. The same INCI list, two different claim routes.
In Korea tranexamic acid can sit in the formula but it cannot carry the whitening claim. The MFDS notice lists nine whitening actives with set contents, from 0.05% up to 2-5%, and tranexamic acid is not on that list. Japan approved the same ingredient as a quasi-drug active in 1995 for preventing rough skin and in 2002 for whitening.
The front panel does not hold the claim
Tranexamic acid turns up in more Korean briefs than almost any other brightening ingredient right now. What it cannot do is put the word whitening on a Korean label. The MFDS Regulation on the Review of Functional Cosmetics notifies nine whitening actives with fixed contents, and tranexamic acid is not one of them.
Not notified is not the same as not permitted. No rule blocks the ingredient from a formula, so it goes in. What closes is the short route — the one where a single report earns the claim. The question to put on a quotation is not how much tranexamic acid is in it, but which ingredient the whitening claim is resting on.
| Korea's nine notified whitening actives | Notified content |
|---|---|
| Niacinamide | 2-5% |
| Arbutin | 2-5% |
| Ethyl ascorbyl ether | 1-2% |
| Magnesium ascorbyl phosphate | 3% |
| Broussonetia extract | 2% |
| Ascorbyl glucoside | 2% |
| Ascorbyl tetraisopalmitate | 2% |
| Alpha-bisabolol | 0.5% |
| Oil-soluble licorice extract | 0.05% |
| Tranexamic acid | not listed |
Off the list, the cost moves into the test calendar
There is still a path if you want the claim on tranexamic acid itself. An ingredient outside the notice goes through review rather than report. Article 9 of the enforcement rule asks for five document sets, and once the file is complete the statutory processing period is 60 days.
Those 60 days start after submission, which is the part that gets planned wrong. Designing and running the efficacy and human application studies sits in front of that clock, and a request for supplementary data restarts it on a separate track. The safety set alone bundles six studies: single-dose toxicity, primary skin irritation, mucosal irritation, skin sensitization, phototoxicity and photosensitization, and a human patch test.
| Route | Condition | What it costs you |
|---|---|---|
| Report | Matches notified active, content and dosage form | One filing |
| Review | Ingredient outside the notice (tranexamic acid) | 5 document sets + 60 statutory days |
In practice the gap shows up as a count of SKUs. One product through review is survivable. Five products on the same concept are not, which is why the usual design puts a notified active behind the claim and keeps tranexamic acid in the formula.
In Japan the same molecule is the active
Cross a border and the same molecule changes status. Japan approved tranexamic acid as a quasi-drug active ingredient, first in 1995 for preventing rough skin and then, with whitening added as a further indication, in 2002.
That is where export briefs go sideways. A buyer who read Japanese material arrives treating tranexamic acid as a whitening active, and the Korean label on a Korean-made product will not carry that word. Going the other way, selling the whitening story into Japan means the quasi-drug route rather than ordinary cosmetics, so a Korean functional-cosmetic report number does not transfer.
| Korea | Japan | |
|---|---|---|
| Use in formula | Permitted | Permitted |
| Basis for whitening claim | Not among the nine notified | Quasi-drug active (2002) |
| How the claim is earned | Efficacy and human studies, review | Quasi-drug approval |
One ingredient name asking for different paperwork in each market is a condition to settle before the range grows, not after. Which ingredients are moving which way is in today's ingredient signal.
What got flagged was wording, not content
A Korea Consumer Agency survey published in 2022 shows where the accidents actually happen. Across 20 whitening functional cosmetics advertised on social media, all 20 met their reported arbutin content at 90% or more of the filed amount. Content was not the problem.
The citations landed on advertising copy. Three products advertised efficacy that had never been reviewed or reported, and four presented ingredients with no functional status as though they delivered whitening, or used claims with no basis behind them. Having an ingredient in the formula and being allowed to describe what it does are separate questions.
Products built on tranexamic acid sit unusually close to that line. The name is on the ingredient list and overseas material calls it a whitening ingredient, so whoever writes the product page reaches for the benefit without checking which claim the filing covers.
Three questions for a buyer
First, ask whether the product holds a whitening functional report number and, if so, which ingredient and content it was granted on. If the answer is niacinamide at 2-5%, tranexamic acid is a supporting ingredient with no bearing on the label.
Second, read the product page and carton against the scope of that filing. Whitening language has a habit of migrating onto tranexamic acid during translation in the importing market. Third, if Japan or another market is in the plan, split the routes at the briefing stage rather than after the first production run. To work a direction into a formula and a quotation, the product planner will lay it out.
In short
- Korea notifies nine whitening actives and tranexamic acid is not one of them. It can go in the formula, but a report alone will not earn the claim.
- Claiming on an ingredient outside the notice means the review route: five document sets, six safety studies, and a 60-day statutory processing period.
- Japan approved the same ingredient as a quasi-drug active in 1995 for rough skin and in 2002 for whitening.
- A Korean whitening claim usually rests on niacinamide or arbutin at 2-5%. Check the front-panel name and the claim basis separately.
- In the 2022 Korea Consumer Agency survey, 7 of 20 whitening products were cited on advertising wording rather than on content.
*Sources: notified actives and contents — nine whitening and four wrinkle actives (Dr. Oracle) / review documents and the 60-day period — functional cosmetics review requirements, review of functional cosmetics (Korea Easy Law) / Japanese quasi-drug approval dates — tranexamic acid (Cosmetic Ingredients Online) / advertising survey — Pharmnews on the Korea Consumer Agency survey. Checked 31 October 2026.*
Using tranexamic acid in a Korean private label formula
If you want tranexamic acid in your own product, a Korean private label (OEM/ODM) partner can start from a tested base instead of a blank page. We check the grade, the dose that can legally be claimed in your market and the cost per unit before the first sample, so the label and the formula agree.
Korean cosmetics private label — cost, MOQ and timeline →
Start a sample request · Browse ready formulations
Questions people ask
No. It is not one of the nine notified actives, so the report route is closed. Claiming whitening means commissioning efficacy and human application studies and going through review, with a 60-day statutory processing period.
From a notified active in the same formula. If niacinamide or arbutin is in at 2-5%, that ingredient is what holds the claim. The name on the front of the box and the basis for the claim can be two different things.
Japan approved tranexamic acid as a quasi-drug active ingredient. It went in first in 1995 for preventing rough skin, and whitening was added in 2002. So one formula travels as an ordinary cosmetic in Korea and as a quasi-drug in Japan.
Five document sets under Article 9 of the Cosmetics Act enforcement rule: origin and development history, safety data (single-dose toxicity, primary skin irritation, mucosal irritation, skin sensitization, phototoxicity and photosensitization, human patch), efficacy and human application studies, and standards and test methods. Sunscreens add SPF substantiation.
No. Advertising efficacy outside what was reviewed or reported is where products get flagged. In a Korea Consumer Agency survey published in 2022, 7 of 20 whitening products were cited on wording, not on content.